President, CEO and Chairman of the Board; Co-Founder
Dr. Mickle co-founded KemPharm, Inc. in 2006 with the invention of the company's LAT (Ligand Activated Therapy) prodrug platform. As president, chief executive officer, and chairman of the board, he oversees KemPharm's business and scientific strategy and is instrumental in the ongoing development of the company's pipeline of proprietary prodrugs.
Prior to founding KemPharm, Dr. Mickle served as director of Drug Discovery and CMC at New River Pharmaceuticals where he was the principal inventor of Vyvanse®, a prodrug of amphetamine for the treatment of attention deficit hyperactivity disorder (ADHD). Today, Vyvanse is the branded market share leader in the estimated $15 billion plus ADHD market. The success of Vyvanse along with a robust pipeline of prodrugs targeting ADHD, pain and thyroid dysfunctions, which Dr. Mickle was responsible for creating, led to New River Pharmaceuticals being acquired by Shire Pharmaceuticals, PLC for $2.6 billion.
During his career, he has been granted 44 US patents, 21 EP (Europe) patents and has authored more than 100 patent applications US and worldwide, primarily focused on abuse-deterrent prodrugs in pain management and mental health, including multiple patents for prodrugs of hydrocodone and methylphenidate. Dr. Mickle is also the principal or secondary investigator on several published abstracts and publications.
Dr. Mickle received his Ph.D. degree from the University of Iowa and his B.A. degree from Simpson College.